Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14759451 | 0.79 | CHRNB2 (0.41) | MAPT | |
| SCHEMBL103445 | 0.79 | TSHR (0.40) | — | |
| SCHEMBL8455989 | 0.79 | CHRNB2 (0.41) | MAPT | |
| SCHEMBL11748204 | 0.73 | TSHR (0.32) | MAPT | |
| SCHEMBL7602718 | 0.73 | — | — | |
| SCHEMBL3822564 | 0.72 | MAPT (0.33) | MAPT | |
| SCHEMBL10369020 | 0.72 | MAPT (0.33) | MAPT | |
| SCHEMBL9728294 | 0.72 | KMT2A (0.42) | MAPT | |
| SCHEMBL6461670 | 0.72 | MAPT (0.33) | MAPT | |
| SCHEMBL1863804 | 0.71 | TSHR (0.33) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024097746-A1 | ALKENE CYCLOPROPANATION WITH NICKEL CATALYST ENHANCER AND IMPROVED REARRANGEMENT REACTION | CONAGEN INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| EP-3060535-B1 | PROCESS FOR THE CYCLOPROPANATION OF OLEFINS USING N-ALKYL-N-NITROSO COMPOUNDS | GIVAUDAN SA (CH) | 2020-08-05 | — | — | EP | disclosed |
| US-20170283342-A1 | ORGANIC COMPOUNDS | Givaudan, S.A. (CH) | 2017-10-05 | — | — | US | disclosed |
| US-9718741-B2 | Organic compounds | Givaudan, S.A. (CH) | 2017-08-01 | — | — | US | disclosed |
| US-20160280615-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2016-09-29 | — | — | US | disclosed |
| EP-3060535-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Givaudan S.A. (CH) | 2016-08-31 | — | — | EP | disclosed |
| WO-2015059290-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2015-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283342-A1 | ORGANIC COMPOUNDS | NOC2L, NOS2, NCL | MAPT 841/4885 |
| US-20160280615-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | NOC2L, NPM1, NOS2 | MAPT 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.